Using the target trial emulation based on the cloning, censoring, and weighting method, we found that discontinuing RASi after the onset of hyperkalemia was not related to poorer kidney outcomes but was associated with higher mortality than continuing RASi. Here, MMP19 is linked to Hyperkalemia.